Dravite Therapeutics, Inc.
San Francisco, CA
Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$53.0M of $53.0M
Filed2026-09-03
Days since filing30
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-21
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- JOSEPH SUMExecutive Officer · Director
- SANDEEP KULKARNIDirector
- BARBARA KOSACZDirector
- MATTHEW MOOREExecutive Officer · Director
- JEREMY GOLDBERGDirector
- RISHI GUPTADirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged100% sold1.4 months since first sale
Prior raiseNot flaggedRaised 354% of its prior round, 2 months on$15.0M prior raise, filed 2026-06-24
AmendedNot flaggedD/A on 2026-07-28Amount offered unchanged or not stated
Open roles
On the employer's own careers page · check date not recorded0
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
All filings
Every filing for this company, newest first, amendments includedAlso raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.